Diabetes and Endocrinology Trials

Important Trials in Diabetes and Endocrinology 2023
The ONWARDS3 Clinical Trial
Is Testosterone Therapy Safe for the Heart? Insights from the TRAVERSE Study
Retatrutide Clinical Trial
Orforglipron vs. Type 2 Diabetes: A Breakthrough in Oral Treatment?
Important Trials in Diabetes and Endocrinology 2021
Bone Mineral Density and Turnover After Sleeve Gastrectomy and Gastric Bypass.
SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
STEP 1 : Semaglutide Treatment Effect in People with Obesity
SOLOIST-WHF: Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure.
SCORED : Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
MOBILE : Continuous Glucose MOnitoring in T2D Basal InsuLin UsErs.
Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes
FIDELIO-DKD: Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease
EMPEROR-Preserved: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction.
COMPASS: Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia
AMPLITUDE-O: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
AfterDmab: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation.
ACTIVE : Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
Reproductive Endocrinology
WHI E + P
AMIGOS : Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility
HERS Study
KEEPS Study : Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial
PCOS (LETROZOLE STUDY)
FET
ELITE – The Early versus Late Intervention Trial with Estradiol
PCOS
Diabetes Mellitus
ADVANCE : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
ACCORD : Effects of intensive glucose lowering in type 2 diabetes
CANVAS : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
D2d TRIAL: Vitamin D Supplementation and Prevention of Type 2 Diabetes.
DCCT : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
DPP: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The Diabetes Prevention Program
HAPO: Hyperglycemia and Adverse Pregnancy Outcomes. The HAPO Study Cooperative Research Group
LEADER : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
Look AHEAD – Look Action for HEAlth in Diabetes.
NICE-SUGAR : Intensive versus conventional glucose control in critically ill patients
CREDENCE
DAPA-HF: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
DECLARE-TIMI 58
iDCL: The international Diabetes Closed Loop Trial: The Clinical Acceptance of the Artificial Pancreas
Look AHEAD: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. Look Action for HEAlth in Diabetes.
RENAAL: Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan
UKPDS 33
U500-R (“HOOD study”)
PROactive
1 of 2
Calcium and Bone Metabolism
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
FIT : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
PTH(1-34) : Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
FRAME : Romosozumab Treatment in Postmenopausal Women with Osteoporosis
FREEDOM : Denosumab for prevention of fractures in postmenopausal women with osteoporosis
HORIZON : Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Zoledronic Acid Recurrent Fracture Trial
Pituitary Disorders
PASIREOTIDE B2305 STUDY GROUP : A 12-month phase 3 study of pasireotide in Cushing’s disease
COPEPTIN – A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus
Lipidology and Obesity
RECORD: Rosiglitazone Evaluated for Cardiovascular Outcomes in oRal agent combination therapy for type 2 Diabetes mellitus
4S : The Scandinavian Simvastatin Survival Study
JUPITER – Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
IMPROVE-IT : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
HPS3/TIMI55 : Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
HOPE-3 Trial : Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
ASCEND : Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
CONQUER
CAMELLIA-TIMI 61 : Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
COR1
STAMPEDE : Bariatric surgery versus intensive medical therapy in obese patients with diabetes
ORIGIN N-3 Fatty Acid
ODYSSEY OUTCOMES : Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Hypertension and Adrenal Disorders
SPRINT
SPYRAL HTN-ON MED
Thyroid Diseases
SCH – Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy.
DECISION STUDY
OPTIC – Treatment of Graves’ Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in a Clinical Study
RAI
TABLET – Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. Thyroid AntiBodies and LEvoThyroxine study
WDTC
ZETA Study
Previous Topic
Next Topic

Pituitary Disorders

Diabetes and Endocrinology Trials Pituitary Disorders
Lesson Content
0% Complete 0/2 Steps
PASIREOTIDE B2305 STUDY GROUP : A 12-month phase 3 study of pasireotide in Cushing’s disease
COPEPTIN – A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus
Previous Topic
Back to Course
Next Topic

Accessibility

Visually Impaired Mode
Improves website's visuals
This mode adjusts the website for the convenience of users with visual impairments such as Degrading Eyesight, Tunnel Vision, Cataract, Glaucoma, and others.

Readable Experience

Content Scaling
Default
Text Magnifier
Readable Font
Dyslexia Friendly
Highlight Titles
Highlight Links
Font Sizing
Default
Line Height
Default
Letter Spacing
Default
Left Aligned
Center Aligned
Right Aligned

Visually Pleasing Experience

Dark Contrast
Light Contrast
Monochrome
High Contrast
High Saturation
Low Saturation
Adjust Text Colors
Adjust Title Colors
Adjust Background Colors

Easy Orientation

Mute Sounds
Hide Images
Virtual Keyboard
Reading Guide
Stop Animations
Reading Mask
Highlight Hover
Highlight Focus
Big Dark Cursor
Big Light Cursor
Cognitive Reading
Navigation Keys
Voice Navigation

My Endo Consult

Accessibility Statement

  • myendoconsult.com
  • May 30, 2026

Compliance status

We firmly believe that the internet should be available and accessible to anyone, and are committed to providing a website that is accessible to the widest possible audience, regardless of circumstance and ability.

To fulfill this, we aim to adhere as strictly as possible to the World Wide Web Consortium’s (W3C) Web Content Accessibility Guidelines 2.1 (WCAG 2.1) at the AA level. These guidelines explain how to make web content accessible to people with a wide array of disabilities. Complying with those guidelines helps us ensure that the website is accessible to all people: blind people, people with motor impairments, visual impairment, cognitive disabilities, and more.

This website utilizes various technologies that are meant to make it as accessible as possible at all times. We utilize an accessibility interface that allows persons with specific disabilities to adjust the website’s UI (user interface) and design it to their personal needs.

Additionally, the website utilizes an AI-based application that runs in the background and optimizes its accessibility level constantly. This application remediates the website’s HTML, adapts Its functionality and behavior for screen-readers used by the blind users, and for keyboard functions used by individuals with motor impairments.

If you’ve found a malfunction or have ideas for improvement, we’ll be happy to hear from you. You can reach out to the website’s operators by using the following email admin@myendoconsult.com

Screen-reader and keyboard navigation

Our website implements the ARIA attributes (Accessible Rich Internet Applications) technique, alongside various different behavioral changes, to ensure blind users visiting with screen-readers are able to read, comprehend, and enjoy the website’s functions. As soon as a user with a screen-reader enters your site, they immediately receive a prompt to enter the Screen-Reader Profile so they can browse and operate your site effectively. Here’s how our website covers some of the most important screen-reader requirements, alongside console screenshots of code examples:

  1. Screen-reader optimization: we run a background process that learns the website’s components from top to bottom, to ensure ongoing compliance even when updating the website. In this process, we provide screen-readers with meaningful data using the ARIA set of attributes. For example, we provide accurate form labels; descriptions for actionable icons (social media icons, search icons, cart icons, etc.); validation guidance for form inputs; element roles such as buttons, menus, modal dialogues (popups), and others. Additionally, the background process scans all of the website’s images and provides an accurate and meaningful image-object-recognition-based description as an ALT (alternate text) tag for images that are not described. It will also extract texts that are embedded within the image, using an OCR (optical character recognition) technology. To turn on screen-reader adjustments at any time, users need only to press the Alt+1 keyboard combination. Screen-reader users also get automatic announcements to turn the Screen-reader mode on as soon as they enter the website.

    These adjustments are compatible with all popular screen readers, including JAWS and NVDA.

  2. Keyboard navigation optimization: The background process also adjusts the website’s HTML, and adds various behaviors using JavaScript code to make the website operable by the keyboard. This includes the ability to navigate the website using the Tab and Shift+Tab keys, operate dropdowns with the arrow keys, close them with Esc, trigger buttons and links using the Enter key, navigate between radio and checkbox elements using the arrow keys, and fill them in with the Spacebar or Enter key.Additionally, keyboard users will find quick-navigation and content-skip menus, available at any time by clicking Alt+1, or as the first elements of the site while navigating with the keyboard. The background process also handles triggered popups by moving the keyboard focus towards them as soon as they appear, and not allow the focus drift outside of it.

    Users can also use shortcuts such as “M” (menus), “H” (headings), “F” (forms), “B” (buttons), and “G” (graphics) to jump to specific elements.

Disability profiles supported in our website

  • Epilepsy Safe Mode: this profile enables people with epilepsy to use the website safely by eliminating the risk of seizures that result from flashing or blinking animations and risky color combinations.
  • Visually Impaired Mode: this mode adjusts the website for the convenience of users with visual impairments such as Degrading Eyesight, Tunnel Vision, Cataract, Glaucoma, and others.
  • Cognitive Disability Mode: this mode provides different assistive options to help users with cognitive impairments such as Dyslexia, Autism, CVA, and others, to focus on the essential elements of the website more easily.
  • ADHD Friendly Mode: this mode helps users with ADHD and Neurodevelopmental disorders to read, browse, and focus on the main website elements more easily while significantly reducing distractions.
  • Blindness Mode: this mode configures the website to be compatible with screen-readers such as JAWS, NVDA, VoiceOver, and TalkBack. A screen-reader is software for blind users that is installed on a computer and smartphone, and websites must be compatible with it.
  • Keyboard Navigation Profile (Motor-Impaired): this profile enables motor-impaired persons to operate the website using the keyboard Tab, Shift+Tab, and the Enter keys. Users can also use shortcuts such as “M” (menus), “H” (headings), “F” (forms), “B” (buttons), and “G” (graphics) to jump to specific elements.

Additional UI, design, and readability adjustments

  1. Font adjustments – users, can increase and decrease its size, change its family (type), adjust the spacing, alignment, line height, and more.
  2. Color adjustments – users can select various color contrast profiles such as light, dark, inverted, and monochrome. Additionally, users can swap color schemes of titles, texts, and backgrounds, with over 7 different coloring options.
  3. Animations – epileptic users can stop all running animations with the click of a button. Animations controlled by the interface include videos, GIFs, and CSS flashing transitions.
  4. Content highlighting – users can choose to emphasize important elements such as links and titles. They can also choose to highlight focused or hovered elements only.
  5. Audio muting – users with hearing devices may experience headaches or other issues due to automatic audio playing. This option lets users mute the entire website instantly.
  6. Cognitive disorders – we utilize a search engine that is linked to Wikipedia and Wiktionary, allowing people with cognitive disorders to decipher meanings of phrases, initials, slang, and others.
  7. Additional functions – we provide users the option to change cursor color and size, use a printing mode, enable a virtual keyboard, and many other functions.

Browser and assistive technology compatibility

We aim to support the widest array of browsers and assistive technologies as possible, so our users can choose the best fitting tools for them, with as few limitations as possible. Therefore, we have worked very hard to be able to support all major systems that comprise over 95% of the user market share including Google Chrome, Mozilla Firefox, Apple Safari, Opera and Microsoft Edge, JAWS and NVDA (screen readers), both for Windows and for MAC users.

Notes, comments, and feedback

Despite our very best efforts to allow anybody to adjust the website to their needs, there may still be pages or sections that are not fully accessible, are in the process of becoming accessible, or are lacking an adequate technological solution to make them accessible. Still, we are continually improving our accessibility, adding, updating and improving its options and features, and developing and adopting new technologies. All this is meant to reach the optimal level of accessibility, following technological advancements. For any assistance, please reach out to admin@myendoconsult.com

Login
Accessing this course requires a login. Please enter your credentials below!

Lost Your Password?